Clinical Data Lilly’s ‘triple G’ retatrutide aces crucial obesity trial PharmaphorumLilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum Lilly’s retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug. Metabolic & GLP-1 Read full story Post navigation Previous: Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rollingNext: Lilly’s triple agonist shows bariatric surgery-like weight loss results Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026